IRMD Iradimed Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRMD

Price (delayed)

$85.55

Market cap

$1.09B

P/E Ratio

47.01

Dividend/share

$1.27

EPS

$1.82

Enterprise value

$1.03B

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 94

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible products in the United States and internationally. It offers non-magnetic intravenous (IV) infusion pump systems, IV tubing sets, ...

Highlights
Iradimed's quick ratio has increased by 37% from the previous quarter and by 9% YoY
The company's revenue rose by 11% YoY
IRMD's price to earnings (P/E) is 15% higher than its 5-year quarterly average of 41.1 but 6% lower than its last 4 quarters average of 50.5
Iradimed's net income has increased by 12% YoY but it has decreased by 2.4% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.iradimed.com
Peers: COO DXCM EW

Key stats

What are the main financial stats of IRMD

IRMD stock price

How has the Iradimed stock price performed over time
Intraday
-0.93%
1 week
3.4%
1 month
-1.87%
1 year
21.81%
YTD
-12.06%
QTD
-10.48%

Financial performance

How have Iradimed's revenue and profit performed over time
Revenue
$86.34M
Gross profit
$65.5M
Operating income
$27.56M
Net income
$23.05M
Gross margin
75.9%
Net margin
26.7%
The company's operating income rose by 16% YoY
Iradimed's net income has increased by 12% YoY but it has decreased by 2.4% from the previous quarter
The company's revenue rose by 11% YoY
The gross profit is up by 10% YoY

Price vs fundamentals

How does IRMD's price correlate with its fundamentals

Growth

What is Iradimed's growth rate over time

Valuation

What is Iradimed stock price valuation
IRMD P/E details
P/E
47.01
P/B
10.75
P/S
12.67
EV/EBIT
34.79
EV/EBITDA
32.98
EV/Sales
11.99
IRMD's price to earnings (P/E) is 15% higher than its 5-year quarterly average of 41.1 but 6% lower than its last 4 quarters average of 50.5
Iradimed's EPS has increased by 12% YoY but it has decreased by 2.2% QoQ
The price to book (P/B) is 32% higher than the 5-year quarterly average of 8.2 but 7% lower than the last 4 quarters average of 11.7
Iradimed's equity has increased by 8% YoY and by 3.3% QoQ
The price to sales (P/S) is 25% higher than the 5-year quarterly average of 10.2 but 6% lower than the last 4 quarters average of 13.6
The company's revenue rose by 11% YoY

Efficiency

How efficient is Iradimed business performance
The company's return on assets fell by 4.2% QoQ
Iradimed's return on equity has decreased by 4.1% QoQ
Iradimed's return on invested capital has decreased by 2.5% QoQ and by 2.1% YoY
Iradimed's return on sales has increased by 3% YoY

Dividends

What is IRMD's dividend history
Dividend details
DPS
$1.27
Dividend yield
1.48%
Payout ratio
69.8%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Iradimed financials performed over time
Iradimed's quick ratio has increased by 37% from the previous quarter and by 9% YoY
The current ratio is up by 33% since the previous quarter and by 8% year-on-year
The company's debt is 100% lower than its equity
Iradimed's equity has increased by 8% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.